CANVA
30.7.2024 05:31:28 CEST | Business Wire | Press release
Canva, a world leader in visual communication with more than 190 million monthly active users, today announced plans to acquire Leonardo.AI. As one of Australia’s fastest-growing startups, and a leading generative AI content and research company, Leonardo.AI is empowering millions of people to bring their ideas to life through production-quality images and videos. The acquisition complements Canva's offering and enhances the company’s vision to build a world-class suite of visual AI tools, marking this as an important milestone in its AI journey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729977410/en/
Canva will acquire Leonardo.AI, a leading generative AI content and research company (Graphic: Business Wire)
As AI continues to shape the future of work and visual communication, the acquisition will accelerate Canva’s investment in continued research and development while bringing Leonardo’s cutting-edge foundational model to Canva’s community worldwide. From creating assets for marketing and advertising campaigns, to visualizing stunning interior concepts, refining mockups, and producing dynamic videos, Leonardo’s technology has been used to produce more than one billion images in the last 18 months.
For Leonardo.AI this is an opportunity to produce new levels of AI innovation while also growing the organisation’s scale. With Canva’s support, the company’s current trajectory will be supercharged to build an even more creative-centric generative AI platform globally.
“We’re thrilled to welcome Leonardo.AI to Canva - two Australian companies joining forces to bring world-first breakthroughs in AI and creativity," said Cameron Adams, co-founder and Chief Product Officer of Canva. “This field is constantly evolving, and Leonardo’s technical leadership and community impact can’t be overstated. Bringing our worlds together will accelerate each of our teams' work, taking us from strength to strength, and we can’t wait to get started.”
World Leading Generative AI Capabilities
Founded in late 2022, Leonardo’s foundational model empowers millions of people to turn ideas into production-quality visual assets with unprecedented control, speed and style consistency. Creators can generate images in any chosen aesthetic in seconds with simple prompts, create videos, sketch with AI, and custom-train models with their own datasets.
Leonardo's new foundational model, Phoenix, takes creator control to the next level, with unprecedented prompt adherence, coherent, accurate text in images and the ability to generate production-ready assets in one shot.
“Today marks the start of a new chapter which will accelerate the pace we innovate at Leonardo.Ai,” said JJ Fiasson, Founder and CEO, Leonardo.AI. Joining the Canva family means we can invest more deeply in scaling our AI research efforts globally, and move even faster to deliver new features and functionality to creatives worldwide.”
In less than two years since launching, Leonardo.AI has amassed more than 19 million registered users and is used across a wide variety of industries including advertising, marketing, design, entertainment, architecture, fashion, e-commerce and education. The joint effort with Canva will produce new levels of AI technology to not only engage, but to also grow Leonardo’s fast growing user base.
From hobbyists to film directors, architects, and professional designers, Leonardo’s technology delivers advanced creative control that pushes the boundaries of what’s possible in generative AI, while remaining intuitive and accessible. Its models can generate stunning images in styles ranging from strikingly realistic photos to character portraits, anime, painterly styles, and more, while its AI video generation tools can bring almost any concept to dynamic life.
Reimagining Visual Communication
Canva’s recent Visual Economy Report shows that the need for effective, efficient, and compelling visual communication has surged dramatically. AI is now playing an increasingly important role in elevating both productivity and creativity at work. From marketing teams scaling global campaigns by instantly generating ad creative for specific audiences, to designers creating initial drafts and storyboards, generative artificial intelligence is changing the way work gets done.
Leonardo’s world-class technology and foundational model will supercharge Canva’s mission to empower every kind of professional to turn their ideas into designs in an instant, leading to faster, more innovative, and more compelling visual communication.
Leonardo's technology will complement Canva’s Magic Studio, the company’s suite of AI tools, which has been used more than 7 billion times since it launched in 2023. To date, Canva users have elevated their design and creative output leveraging Magic Studio for everything from summarising documents to creating images and turning brainstorm whiteboards into fully-fledged presentations.
Supercharging Canva’s AI Journey
Canva will continue to invest in Leonardo's standalone platform while integrating its technology throughout the company’s suite of Magic Studio products. Working with Leonardo’s team of 120 high-caliber researchers, engineers, and designers will also bolster Canva’s research and development capabilities as the company continues to invest in long-term innovation opportunities.
Acquisitions have played an important role in elevating and accelerating Canva’s technology over the last decade. The acquisition of Leonardo is the company’s 8th acquisition, joining Affinity (2024), Flourish (2022), Kaleido (2021), Smartmockups (2021), Pexels (2019), Pixabay (2019) and Zeetings (2018).
For more details about the acquisition, see Canva Co-Founder Cameron Adams blog post and Leonardo.Ai’s CEO JJ Fiasson’s blog post, respectively.
About Canva
Launched in 2013, Canva is a free online visual communications and collaboration platform with a mission to empower everyone in the world to design. Featuring a simple drag-and-drop user interface and a vast range of templates ranging from presentations, documents, websites, social media graphics, posters, apparel to videos, plus a huge library of fonts, stock photography, illustrations, video footage, and audio clips, anyone can take an idea and create something beautiful.
About Leonardo.Ai
Leonardo.Ai is one of Australia’s fastest-growing startups, democratising creativity with its generative AI content production platform. Since launching in 2022, the company has amassed more than 19 million users worldwide, who have generated over one billion images. Leonardo.Ai is currently being used by both hobbyists and professionals across creative industries such as advertising and marketing, design and architecture, film, fashion, photography, e-commerce, education, and more.
Downloadable Assets
Click here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729977410/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom